EyePoint Pharmaceuticals Inc (FRA:PV3B)
€ 7.932 0.038 (0.48%) Market Cap: 409.05 Mil Enterprise Value: 136.42 Mil PE Ratio: 0 PB Ratio: 1.69 GF Score: 61/100

EyePoint Pharmaceuticals Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript

Apr 28, 2022 / 01:30PM GMT
Release Date Price: €11.2 (+0.90%)
Mayank Mamtani
B. Riley Securities, Inc. - Analyst

Good morning. Welcome back, everyone, to day two of B. Riley Neuro and Ophthalmology Conference. We thank you all for being part of our conference. And it's my great pleasure to introduce our next presenting company, EyePoint Pharmaceuticals.

Here with me, Jay Duker, the Chief Operating Officer. Thanks, Jay, for being part of this event. Maybe we can kick off our discussion by you giving us an overview of EyePoint.

Obviously, a big transformational year for you guys in the past 12 to 18 months. Would maybe love to hear about the platform that got this going. And then also to see the excitement around the wet AMD program, which we can dive deeper.

Jay Duker
EyePoint Pharmaceuticals, Inc. - COO

Sure. Well, thank you very much for the kind invitation. So EyePoint actually has been a publicly traded company for over 20 years. And its initial product was based on the current sustained-release technology that we call Durasert. It was an implant for CMV retinitis in HIV positive patients. And,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot